Three recent cases of fatal reactions to low-dose oral methotrexate due to interactions and dosing errors highlight the need to improve safety.
Source: 10 Ways to Avoid Fatal Methotrexate Errors | Rheumatology Network
Three recent cases of fatal reactions to low-dose oral methotrexate due to interactions and dosing errors highlight the need to improve safety.
Source: 10 Ways to Avoid Fatal Methotrexate Errors | Rheumatology Network
In a registry-based cohort study, Seena Fazel and colleagues test for within-individual associations between SSRI prescription and violent crime.
Source: PLOS Medicine: Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study
I’ve cut and pasted an email from Health After 50, a free newsletter from Scientific American. My first thought was dig deeper. The uninformed masses might take this information to their physician and start creating demand for these drugs. Would you be surprised that the cost could be as high as $1000.00 per month?
PCSK9 Inhibitors: The Needle, the Cost, the Barriers | Medpage Today
There are still some highly effective generic statins where $10.00 buys you a 90 day supply. There are OTC options to help with muscle pain and cramps. You have to ask what good will these new drugs do if no one can afford them?
God Bless America. We now have PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors.
The Promising Alternative to Statins
Every so often medication comes along that sends the world of medicine’s collective heart aflutter. Cholesterol-lowering newcomers alirocumab (Praluent) and evolocumab (Repatha) are the current favorites.
Both medications are part of a new class of drugs called PCSK9 inhibitors. As the “inhibitor” in the name implies, these drugs work by inhibiting proprotein convertase subtilisin/kexin 9, a protein that makes it more difficult for the liver to remove cholesterol. By blocking this substance, the medication is able to lower the LDL cholesterol circulating in the blood. In clinical trials, PCSK9 inhibitors have been shown to lower LDL levels significantly beyond what can be achieved with statin drugs, which have been the standard cholesterol-lowering therapy for more than two decades. And they did so without the most common side effect of statins: muscle pain.
There are multiple links in the WP article to the original studies.
FDA Stiffens Warning on NSAID Cardiovascular Risk | Medpage Today.
Thought I would add a link to the actual FDA alert.
NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease. A large number of studies support this finding, with varying estimates of how much the risk is increased, depending on the drugs and the doses studied.
There’s also the issue of cost. The medicines are expected to come with a price tag of $7,000 to $12,000 per patient per year, according to the Wall Street Journal’s Pharmalot blog, costing the US health system as much as $23 billion a year. “These injectable drugs are already viewed by payers as potential budget busters along the lines of treatments for hepatitis C and some cancers,” Ed Silverman wrote.
via There’s still a lot we don’t know about the new cholesterol-lowering drugs – Vox.
PodMed: A Medical News Roundup From Johns Hopkins | Medpage Today.
Digoxin and mortality at the six minute mark of the podcast is a must listen.
According to some reports metformin poisoning, though rare, is associated with a mortality rate of 30%.
via Hemodialysis in metformin poisoning | The Poison Review.
Yikes.
“When we see something that surprises us and flies in the face of what is understood, it requires another look — maybe a different cohort, larger numbers, longer follow-up,”
via Intensive Tx Fails to Slow Atherosclerosis | Medpage Today.
Surprised? As long as we continue to focus on pharmaceuticals as the answer, no one should be surprised.
You must be logged in to post a comment.